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Leukemia inhibitory factor ameliorates experimental anti-GBM Ab
glomerulonephritis. Leukemia inhibitoiy factor (LIF) is a pleiotropic
cytokine that has been identified in acute and chronic inflammatory
conditions such as rheumatoid arthritis, sepsis, and renal allograft rejec-
tion. We investigated the glomerular expression of LIF at 30 minutes, and
3, 6, 9, 15 and 24 hours after administration of anti-GBM Ab (N = 3) by
the RNase protection assay. Control rats received rabbit sera and were
sacrificed at 30 minutes, and 6 and 24 hours. LIF mRNA relative to
GAPDH mRNA was detected at low levels within the glomeruli of
occasional control rats. However, with the induction of anti-GBM Ab GN,
there was a marked increase in LIF steady-state mRNA beginning at three
hours which persisted through 24 hours. LIF mRNA was also detected in
cultured mesangial cells stimulated with TL-1J3, identifying this cell type as
a potential glomerular source for this cytokine. To investigate the in vivo
effect of LIF, Lewis rats were continuously infused with recombinant (r)
human (h) LIF (--0.5 ng/hr) or saline vehicle i.p. with ALZA osmotic
pumps beginning at t = —24 hours (N = 8). All rats were injected with
anti-GBM Ab intravenously at t = 0 (N = 16). LIF infusion decreased
24-hour urinary protein excretion by 85% (17 15 vs. 114 37 mg/day,P = 0.0001) and was associated with a 60% decrease in glomerular
macrophage infiltration (0.8 0.2 vs. 2.0 0.6 ED-I cells/glom, P =
0.0001). The administration of rhLIF did not affect the binding of the
anti-GBM Ab to glomeruli. The beneficial effects of LIF were associated
with a decrease in glomerular MCP-I (56%), IL-i (41%) and TNF (17%)
steady state mRNA expression. The latter was associated with a 29%
decrease in TNF-a protein expression within the glomerular lysate of
nephritic rats administered LIF when compared with control rats. These
data demonstrate a potential role for LIF in the therapy of anti-GBM Ab
GN.
ytokines are polypeptides that are important mediators of
inflammation by regulating the proliferation, differentiation, mo-
bility and function of effector cells. Within the past decade, an
important role has been defined for many of these cytokines in the
pathogenesis of inflammation [reviewed in 1—51. Through a com-
plicated cascade which often feeds back onto itself, interleukin 1
(IL-i) and tumor necrosis factor (TNF) induce the expression of
chemokines such as IL-8 and MCP-I [4], cell adhesion molecules
[5], procoagulant activity [6] and collagenase secretion [7], and
augment leukocyte phagocytosis and cytotoxic activity [8]. More
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recently, a number of cytokines with anti-inflammatory properties
including the IL-i receptor antagonist (ra), IL-4, IL-6 and IL-iD
have been identified. For example, the latter three cytokines
induce IL-Ira [9, 10], which in turn inhibits IL-I activity by binding
to its receptor [II], while IL-4 down-regulates prostaglandin, IL-I,
TNF and interferon-y production [12, 13]. Similarly, IL-lU inhibits
IL-i, IL-8, TNF, and nitric oxide production by neutrophils
(PMNs) and/or macrophages [14, 15].
Cytokines are believed to be important in the pathogenesis of
antiglomerular basement membrane (GBM) antibody (Ab) gb-
merulonephritis (GN). The importance of pro-inflammatory cy-
tokines in this disease is now well established. Therefore, neutral-
ization of IL-i and TNF activities has been shown to decrease
gbomerular neutrophil (PMN) and macrophage infiltration as well
as to attenuate proteinuria [16, 17]. More recently, there are data
to suggest that anti-inflammatory cytokines may also be involved.
For example, IL-Ira is found in the sera of rats with a-GBM Ab
UN, suggesting that mechanism(s) are activated to counteract
glomerular inflammation while the pharmacologic administration
of IL-Ira has been reported to be beneficial [16]. Similarly,
administration of IL-4 and IL-6 to rats with anti-GBM Ab GN was
reported to cause a 60 to 80% reduction in glomerular thrombi
formation and urinary protein excretion [18].
Leukemia inhibitory factor (LIF) is a member of an unusual
family of proteins known as the neuropoietic cytokines with
pleiotropic properties which affects numerous cell types [19].
Together with ciliary neurotrophic factor, oncostatin M, interleu-
kins (IL) 6 and II, these cytokines bind to a unique a-receptor
subunit that associates with a common gpl3O receptor subunit
that initiates signal transduction [20]. The role of LIF in the
pathogenesis of inflammation remains uncertain since both ben-
eficial and detrimental effects have been ascribed to this cytokine.
LIF has been demonstrated to decrease pulmonary PMN infiltra-
tion following intratracheal LPS injection [21]. In addition, serum
concentrations of LIF are elevated in patients with septic shock
and correlate with disease activity [22], while pretreatment with
LIF protects against experimental E. coli induced sepsis [23, 24].
However, this would appear to be inconsistent with another report
that showed passive immunization of mice against LIF prevents
lethal endotoxemia [25]. Therefore, the present study was per-
formed to determine the role of LIF in the pathogenesis of
anti-GBM Ab GN.
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Methods
In Vitro studies
Rat mesangial cells were a generous gift from Dr. Hanna
Abboud (UTHSC, San Antonio, TX, USA) and had been previ-
ously characterized in his laboratory. The mesangial cells were
plated onto 100 X 20 mm tissue culture plates in RPM! 1640 with
10% fetal calf serum (FCS). When the cells had grown to 80%
confluency, the cells were starved for 15 to 16 hours in serum free
RPMI 1640. IL-1/3 (1 ig/ml) or media (without FCS) were added
to the plates at time zero and the cells were harvested at 1, 4, 8
and 24 hours. The preparation of total RNA from the rat
mesangial cells is described below.
Experimental model
Normal rabbit serum (NRS) was obtained by bleeding naive
unimmunized rabbits while a-GBM Ab was prepared by immu-
nizing New Zealand white rabbits with rat GBM as previously
described [16]. Both the a-GBM Ab serum and NRS were
decomplemented and absorbed with Lewis rat erythrocytes.
Twenty-seven Lewis rats (Charles River Lab, Wilmington, MA,
USA) were injected with 0.5 ml of either a-GBM Ab (N = 18) or
NRS (N = 9) intravenously. Three rats with a-GBM Ab GN were
euthanized at the following time points: 30 minutes, and 3, 6, 9, 15
and 24 hours. Control rats were euthanized at 30 minutes, 6 and
24 hours.
The role of LIF in a-GBM Ab GN was investigated by
administering LIF to Lewis rats prior to the induction of nephritis.
A different a-GBM Ab was used for these experiments than had
been used in the preceeding time course study. The preparation
and characterization of recombinant human LIF (rhLIF) from a
synthetic gene has been described previously [26]. The ability of
rhLIF to exert a biologic effect in rat tissues has been previously
demonstrated [26]. Alzet microosmotic pumps (model 1003D;
Aiza Corp., Palo Alto, CA, USA) loaded with rhLIF (N = 8) or
saline vehicle (N = 8) were implanted into the peritoneum of
Lewis rats under isoflurane anesthesia at —24 hours. The 24-hour
time point was chosen so that the rats had sufficient time in which
to recover from the stress of surgery and anesthesia. The pumps
were calibrated to deliver 0.98 0.02 rd/hr which corresponds to
—0.52 ng LIF/hr. All rats were administered a-GBM Ab (N 16)
at t = 0 and a 24 hour urine was collected for determination of
urinary protein excretion. Proteinuria was quantitated by the
sulfosalicylic acid method with rat albumin (Sigma Chemical Co.,
St. Louis, MO, USA) serving as the standard. The rats were
sacrificed at 24 hours and renal tissue was prepared for histologic
evaluation. In addition, glomeruli were isolated by sieving and
prepared for protein (N 6) or RNA (N = 10) analysis.
Morphologic studies
Renal tissue was fixed in 10% formalin for light microscopy and
immunohistochemistry. Histologic sections were stained with the
periodic acid-Schiff reaction and hematoxylin counterstain. Im-
munohistochemistry was performed on deparaffinized sections
that were incubated with a murine monoclonal Ab to rat mono-
cyte/macrophage, ED-i (Harlan Bioproducts for Science, Inc.,
Indianapolis, IN, USA). Clone ED-i was detected using horse-
radish peroxidase ABC reagents from BioTek (Santa Barbara,
CA, USA) with DAB as the chromagen. Glomerular monocyte/
macrophage infiltration was determined by counting the number
of cells expressing ED-i in 25 consecutive glomeruli with similar
cross section diameters. Data are presented as the mean sum of
variances.
Quantitation of steady state mRNA
Riboprobes for rat IL-i/3 [129 nucleotides (n)], TNF-a (184 n)
and LIF (139 n) were prepared by RT-PCR from rat spleen or
endotoxin stimulated macrophage RNA. Primers (24-mers) based
upon the rat LIF [27] and TNF-a cDNAs [28] and degenerate
primers based upon homologous regions within the cDNAs of
human and murine IL-i /3 [29, 30] were synthesized on an Applied
Biosystems automated DNA synthesizer. The sequences of the 5'
and 3'-primers were:
LIF 5 '-primer: 5 -GCGCCATACGCCACCCGTGTCACG-3'
3 '-primer: 5 '-TTATCCACGTflI'G'TTGGGAAATGGT-3'
IL-i/3 5 '-primer: 5 '-AAAATACCTGTGGCcTFGGGCCTC-3'
3 '-primer: 5' -(TC)TTTICCATCTflI'CYrCTTFGGGTA-3'
TNF-a 5-primer: 5'-GTGGTGGTACCAGCAGATGGGGFG-3'
3 '-primer: 5 '-TCAGCTCCCTCAGGGGTGTCCTFA-3'
After reverse transcription, PCR was performed for 40 cycles
under the following conditions: denaturing at 94°C, annealing at
54°C, and elongating at 72°C. The RT-PCR product was purified
on agarose, ligated into pGEMT (Promega, Madison, WI, USA)
and then sequenced with a Taq DyeDeoxy Terminator cycle
sequencer kit (Applied Biosystems, Inc.) on an automated DNA
sequenator (Applied Biosystems 373A). The sequences of the
RT-PCR generated LIF and TNF-a were identical to the pub-
lished rat cDNAs while IL-ip was 97% and 100% homologous to
the corresponding murine nucleic acid and deduced amino acid
sequences, respectively [30].
The details of the PCR cloning of the rat monocyte chemoat-
tractant protein-i (MCP-1) and GAPDH riboprobes and of the
RNase protection assay have been described previously [31].
Briefly, glomeruli (> 90% purity) from the kidneys of rats
administered either a-GBM Ab (N = 18) or NRS (N = 9) in the
time course study and from rats in the subsequent LIF adminis-
tration study (N = 10) were prepared by sieving. Glomerular and
mesangial cell total RNA was isolated by acid phenol/chloroform
extraction and frozen at —70°C until assayed. Anti-sense ribo-
probes for IL-1/3, TNF-a, MCP-1, LIF and GAPDH were pre-
pared by in vitro transcription with SP6 or T7 RNA polymerases
(Ambion, Austin, TX, USA) and the incorporation of cx32P-UTP
(Amersham Corp., Arlington Heights, IL, USA) at 37°C. The
riboprobes were purified on 6% polyacrylamide gel and then
eluted with 0.5 M NH4OAc. Glomerular RNA (2 jsg) from the
time course study (18 anti-GBM Ab GN and 9 control rats) was
hybridized with I x i0 counts of 32P-UTP-labeled LIF and
GAPDH riboprobes for 14 to 16 hours at 56°C while 2 rg of RNA
from the LIF administration study (N = 6) was hybridized with
IL-ij3, TNF-a, MCP-i and GAPDH under the same conditions.
The unhybridized RNA was digested with RNase A and Ti
(Ambion) at 30°C for one hour. The RNases were then digested
with proteinase K (Boehringer Mannheim) at 37°C for 30 min-
utes. After phenol/chloroform extraction and sodium acetate/
ethanol precipitation, the samples were eleetrophoresed on 6%
polyacrylamide gel. The radioactivity of the protected 32P-UTP
labeled riboprobes were quantitated with a Phosphorimager (Mo-
lecular Dynamics, Sunnyvale, CA, USA).
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Quantitation of a-GBM Ab binding
To insure that rhLIF did not interfere with the binding of the
a-GBM Ab, a-GBM Ab was eluted from the glomeruli of
nephritic rats that had been administered rhLIF (N = 3) or saline
(N = 3) by sonification and quantitated with an ELISA. A 96-well
ETA/RIA flat bottom plate (Costar Corp., Cambridge, MA, USA)
was coated overnight with the glomerular lysate at 4°C. After
blocking with 1% bovine serum albumin/5% sucrose in TRIS!
EDTA, the plate was incubated with horseradish peroxidase
conjugated swine is-rabbit IgG (DAKO Inc., Carpinteria, CA,
USA) at 25°C for one hour, washed with 0.02% Tween 20, and
then developed with hydrogen peroxide and 3,3',5,5'-tetramethyl-
benzidine for five minutes. The reaction was quenched with
phosphoric acid and the optical density at 450 nm was determined
on a Thermomax microplate reader (Molecular Devices, Menlo
Park, CA, USA). A reference curve was generated from known
concentrations of afinity purified rabbit IgG (Jackson Immuno-
Research, West Grove, PA, USA) which was assayed in parallel.
Samples were assayed in triplicate and data are presented relative
to the protein concentration which was determined by a commer-
cial colorimetric assay (Sigma).
Determination of TNF-cs
Glomerular lysate from rats with anti-GBM Ab GN that had
been administered either LIF (N = 3) or saline vehicle (N = 3)
were assayed for TNF-a with a sandwich ELISA (BioSource Int'l,
Camarillo, CA, USA) using rabbit and hamster polyclonal Abs to
rat TNF-a. Samples were assayed in triplicate and normalized for
the protein content present within each sample as described
above.
Statfvtical methods
Data are presented as the mean SD or mean sum of
variances. Statistical analyses were performed by comparing indi-
vidual group means using the unpaired Student's t-test. A P < 0.05
was considered significant.
Results
In vitro studies
Rat mesangial cells cultured in 0% or 10% FCS did not express
LIF mRNA at the time points studied. By comparison, there was
a rapid induction of LIF mRNA relative to GAPDH mRNA one
hour after the addition of IL-lp (Fig. 1). The steady state
expression of LIF mRNA relative to GAPDH mRNA remained
essentially unchanged through 24 hours.
Expression of LIE in a-GBM Ab GN
The glomerular pathology of the 27 rats in the time course study
(0.5 to 24 hr) has been described in a previous communication
[31]. Briefly, there was a diffuse infiltrative GN composed of
primarily PMNs after induction of anti-GBM Ab GN that peaked
at three hours and was replaced by a diffuse monocyte/macro-
phage infiltration that peaked at 24 hours. There was a low
constitutive expression of LIF mRNA within the glomeruli of
occasional control rats that had been administered NRS at the
three time points examined. Similarly, rats with anti-GBM Ab GN
at the 30-minute time point had minimal to no expression of LIF
mRNA (Fig. 2). An increase in LIF mRNA was detected within
the glomeruli of rats with anti-GBM Ab GN at three hours. The
steady state expression of LIF mRNA relative to GAPDH mRNA
peaked at three to six hours and declined thereafter, but was still
present albeit at lower levels by 24 hours (Fig. 3). Unfortunately,
attempts to identify the LIF protein within either the mesangial
cell conditioned media or glomerular lysate with monoclonal and
polyclonal Abs which recognizes human LIF were unsuccessful.
Administration of LIF ameliorates cs-GBM Ab GN
The role of LIF in the pathogenesis of anti-GBM Ab GN was
assessed by the continuous infusion of rhLIF. There was a 60%
decline in glomerular macrophage infiltration (0.8 0.2 ED-I
cells/glom) in rats infused with rhLIF when compared with rats
that had received the saline vehicle (2.0 0.6 ED-i cells/glom,
P = 0.0001). This was accompanied by a 85% decrease in 24-hour
urinary protein excretion (17 15 vs. 114 37 mg/day, P =
0.0001). The administration of rhLIF did not affect the binding of
the s-GBM Ab (186.3 18.7 ng rabbit IgG/mg glom lysate) when
compared with rats that had received the saline vehicle (180.5
8.7 ng rabbit IgG/mg glom lysate).
To determine if the administration of rhLlF affected cytokine
expression, glomerular RNA was assessed for the presence of
IL-lp and TNF-a mRNA. The administration of rhLIF prior to
the induction of nephritis decreased the steady state expression of
IL-1f3 and TNF-a mRNAs (relative to GAPDH mRNA) when
compared with rats that had received saline. There was a 41%
reduction in IL-1f3 steady state mRNA expression from 0.17
0.04 to 0.10 0.02 with rhLIF treatment (P = 0.009). Similarly,
there was a 17% decline in TNF-cs steady state mRNA expression
(0.10 0.01 vs. 0.12 0.01, P = 0.04). The decline in TNF-a
mRNA expression was confirmed at the protein level with an
ELISA. There was a 29% reduction in TNF-a protein expression
within the glomerular lysate of rats administered LIF (1717 264
pg/mg glom lysate) relative to control rats (2415 154 pg/mg
GAPDH
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Fig. 1. Autoradiography of a RNase protection
assay demonstating increased mesangial cell
expression of LIF mRNA relative to GAPDH
mRNA 1, 4, 8 and 24 hours after the addition of
IL-1/3 (+). In contrast, neither cells cultured in
serum free media (0% FCS), 10% FCS, or
vehicle (—) expressed LIF mRNA.
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Fig. 2. Autoradiography of a RNase protection assay demonstrating increased LIF steady state mRNA expression relative to GAPDH mRNA 0.5, 3, 6, 9, 15
and 24 hours after induction of a-GBM Ab GN (+). Occasional control rats that had received NRS (—) were sacrificed at 0.5, 6 and 24 hours and
expressed low levels of LIF mRNA.
0.00
Time, hours
Fig. 3. A temporal profile of LIF steady state mRNA expression relative to
GAPDH mRNA in anti-GBMAb GN was determined by quantitation of the
RNase protection assay with a Phosphorimager. Occasional control rats
expressed LIF mRNA which was below the limit of quantitation while LIF
mRNA was up-regulated in rats with anti-GBM Ab GN beginning three
hours after induction of GN. Each point represents the mean SD of 3
rats that were assayed individually.
glom lysate, P < 0.02). These changes in cytokinc expression were
associated with a 56% decrease in the glomerular steady state
mRNA expression of the C-C chemokinc, MCP-1, in rats treated
with LIF (0.04 0.02 vs. 0.09 0.04, P = 0.02).
Discussion
These experiments demonstrate a potential role for LIF in the
pathogenesis of heterologous phase anti-GBM Ab GN. There was
an increase in the steady state expression of LIF mRNA relative
to GAPDH mRNA within the glomeruli of nephritic rats three
hours after induction of anti-GBM Ab GN. Although we were
unable to confirm the presence of the LIF protein with Abs that
recognizes human LIF, it is likely that the mRNA was translated
since complete dissociation of mRNA expression and protein
translation is rare. In addition, these data are consistent with
previous studies that have demonstrated elevated levels of LIF in
patients with a variety of acute and chronic inflammations includ-
ing sepsis [22], arthritis [32], and renal transplantation [33]. In the
latter group of patients, LIF was identified within the urine but
not in the serum of renal allograft recipients during episodes of
acute rejection. Similarly, LIF has been demonstrated within the
serum [23, 25] and bronchoalveolar lavage fluid [21] of rodents
following endotoxin instillation.
LIF exhibits a broad spectrum of biologic activities that seem-
ingly appear to be unrelated [18]. Initially described as a factor
which induces the differentiation of murine Ml leukemia cells,
LIF also regulates differentiation, growth, metabolism, and in-
flammation [181. It is produced by a variety of cells including
fibroblasts [34], monocytes/macrophages [35], osteoblasts [36], T
lymphocytes [37] and endothelial cells [38] in response to endo-
toxin and inflammatory cytokines such as IL-i and TNF. Based
upon the data presented, glomerular mesangial cells may now be
added to this list. Mesangial cells have been shown to produce a
variety of inflammatory cytokines including IL-i, IL-6 and TNF
[39—41]. More recently, mesangial cells were reported to secrete
IL-b that inhibited endotoxin induced TNF-a production [42].
The ability of mesangial cells to produce IL-b and LIF suggest
that this cell type possesses the capability to autoregulate inflam-
mation by producing pro- and anti-inflammatory cytokines.
The continuous infusion of rhLIF produced a 60% decline in
glomerular monocyte/macrophage infiltration which was associ-
ated with an 85% decrease in urinary protein excretion at 24
hours. The ability of rhLIF to interact with rat tissues has been
previously demonstrated both in vitro and in vivo [21, 261. A
0.03
0.02
0.01
z
a:
EI0
a-
0
z
a:
E
LL
-J
0 5 10 15 20 25
1926 Tang et al: LIF ameliorates a-GBMAb GN
continuous infusion of rhLIF was chosen due to the short half-life
of this peptide (6 to 8 mm) with the kidneys being the major site
of clearance [43]. The beneficial effect of rhLIF was not related to
alterations of the GN since rhLIF administration did not affect
glomerular binding of the a-GBM Ab. The beneficial effect of
rhLIF was associated with a decrease in the expression of the
inflammatory cytokines, IL-1/3 and TNF-a, and of the chemokine,
MCP-1, within the glomeruli of nephritic rats. The latter chemo-
kine has been shown to be an important mediator of glomerular
macrophage infiltration in anti-GBM Ab GN [44]. These results
are similar to those reported by Ulich et al in which the intratra-
cheal administration of rhLIF decreased TNF expression within
the alveolar lavage fluid by 60% [211. In contrast, IL-4 decreased
albuminuria by 60 to 80% in anti-GBM Ab GN but did not affect
glomerular IL-i mRNA expression [18].
In conclusion, these data demonstrate rapid up-regulation of
LIF mRNA following the induction of anti-GBM Ab GN with the
mesangial cell as a potential site of LIF production. The pharma-
cologic administration of rhLIF demonstrates that this cytokine
functions to down-regulate inflammation within the glomerulus.
rhLIF decreased glomerular macrophage infiltration by 60% 24
hours after the induction of anti-GBM Ab GN, which was
associated with an 85% reduction in proteinuria. The beneficial
effect of rhLIF was associated with decreased cytokine and
chemokine production. The efficacy of rhLIF in experimental
anti-GBM Ab GN suggests a potential role for this cytokine in the
therapy of glomerular inflammation.
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